RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been given a consensus recommendation of “Hold” by the six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $3.00.

A number of brokerages have issued reports on RAPT. HC Wainwright raised shares of RAPT Therapeutics to a “strong-buy” rating and set a $6.00 target price for the company in a report on Thursday, May 22nd. UBS Group dropped their target price on shares of RAPT Therapeutics from $2.00 to $1.00 and set a “neutral” rating for the company in a report on Thursday, May 22nd. Finally, Wall Street Zen raised shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RAPT. TCG Crossover Management LLC purchased a new position in shares of RAPT Therapeutics during the 4th quarter worth approximately $19,751,000. Orbimed Advisors LLC purchased a new position in shares of RAPT Therapeutics during the 4th quarter worth approximately $20,754,000. Foresite Capital Management VI LLC purchased a new position in shares of RAPT Therapeutics during the 4th quarter worth approximately $19,750,000. RTW Investments LP purchased a new position in shares of RAPT Therapeutics during the 4th quarter worth approximately $18,587,000. Finally, BVF Inc. IL purchased a new position in shares of RAPT Therapeutics during the 4th quarter worth approximately $14,595,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Trading Up 6.0%

Shares of RAPT Therapeutics stock opened at $0.94 on Tuesday. RAPT Therapeutics has a 12-month low of $0.71 and a 12-month high of $4.60. The stock has a market cap of $124.10 million, a PE ratio of -0.34 and a beta of -0.04. The company has a 50-day moving average of $0.93 and a two-hundred day moving average of $1.12.

RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.23. On average, sell-side analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.